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ackground: Cyclin-Dependent Kinase-2 (CDK2) is a member of serine/threonine protein kinases 
family and plays an important role in regulation of various eukaryotic cell division events. Over-
expression of CDK2 during cell cycle may lead to several cellular functional aberrations including 
diverse types of cancers (lung cancer, primary colorectal carcinoma, ovarian cancer, melanoma 
and pancreatic carcinoma) in humans. Medicinal plants phytochemicals which have anticancer potential 
can be used as an alternative drug resource.  
Methods: This study was designed to find out anticancer phytochemicals from medicinal plants which 
could inhibit CDK2 with the help of molecular docking technique. Molecular Operating Environment 
(MOE v2009) software was used to dock 2300 phytochemicals in this study.  
Results: The outcome of this study shows that four phytochemicals Kushenol T, Remangiflavanone B, 
Neocalyxins A and Elenoside showed the lowest S-score (-17.83, -17.57, -17.26, -17.17 respectively) and 
binds strongly with all eight active residues Tyr15, Lys33, Ileu52, Lys56, Leu78, phe80, Asp145 and Phe146 
of CDK2 binding site. These phytochemicals could successfully inhibit the CDK2. 
Conclusion: These phytochemicals can be considered as potential anticancer agents and used in drug 
development against CDK2. We anticipate that this study would pave way for phytochemical based novel 
small molecules as more efficacious and selective anti-cancer therapeutic compounds. 
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Introduction  
In multicellular organism cell cycle is a synchronized 
chain of events directed by number of intracellular and 
extracellular signaling proteins which operate to 
maintain the fidelity of DNA content [1]. Central to cell 
cycle specific signaling protein repertoire are Cyclin 
Dependent Kinases (CDKs) complexed with cyclins. 
Cell cycle encompasses interphase and Mitotic phase, 
where interphase is morphologically categorized in G1, 
S and G2 phase. CDKs-Cyclin complexes act at check 
points during progression of events in cell cycle. They 
specifically guard the DNA content of cell and decide 
fate of cell to further move in cell cycle or not. CDKs 
belong to family of serine/threonine kinases that are 
activated at certain stages of interphase [2]. Activity of 
CDKs is regulated through a pattern of phosphorylation 
and dephosphorylation at conserved serine/threonine 
residues by proteins i.e. p40m015 as well as its binding 
with cyclin box on its partner cyclin [3]. In cell cycle 
progression decision, by far six mammalian CDKs 
complexed with 13 eukaryotic cyclin proteins at 
different events have been identified. In interphase, G1 
phase characterized as phase of gap in which cell prepare 
itself for growth while CDK4, CDK5 and CDK6 in 
complex with cyclin D ensures the correctness of genetic 
content. Transition from G1 to synthesis (S) phase is 
critically regulated by CDK2-cyclin E complex. At this 
checkpoint, in case of any DNA content infidelity in cell, 
progression will be arrested to enter in S phase and p53 
gene is activated for DNA repair. Once cell reaches in S 
phase, CDK2-cyclin A complex maintains a critical 
check on cells to let the healthy cell win the battle of 
survival within the human body [4]. Multiple cancer i.e. 
lungs cancer, primary colorectal carcinoma, ovarian 
cancer, melanoma, and pancreatic carcinoma have been 
reported due to over-expression or down regulation of 
CDK2 [5].  
Asia accounts for 56% of total world’s population, add 
44% to total global burden of cancer and contributes 
51% to overall death toll globally [6-9]. CDKs are 
considered deliberate anticancer drug target to limit 
replicative potential of tumor cells. Therefore, small 
molecule CDK2 inhibition can play an important role in 
controlling the cancer and become a potential target for 
cancer therapy [10]. Therapeutic interventions of CDK2 
inhibitors has been extensively studied in cancer and 
other proliferative diseases. Intensive research has led to 
discovery of 21 inhibitors that are known to block the 
activity of 11 isoforms of CDKs. Approximately 20 of 
them are in clinical trials.  AG-024322 (Pfizer), AT7519 
(Astex) and alvocidib another name of flavopiridol 
(sanofi-Aventis) are CDK2 specific inhibitors currently 
in pre-clinical studies. Recently in February 2015, 
palbociclib (Pfizer, Ibrane®), a CDK4, CDK6 inhibitor 
has been launched in market after Food and Drug 
Administration (FDA) approval [11-13]. For CDK2 
inhibitors clinical data reports multitarget potential 
which negatively affect interconnected signaling 
pathway and produce undesired side effects. To discover 
specific CDK2 inhibitors with desired activity in 
addition to minimal effect on downstream signalosome 
and undesired effects, we need to direct our research on 
screening and development of phytochemical based 
small molecules library screening [5,14]. 
Medicinal plants are the natural source of therapeutic 
agents. A remarkable number of modern drugs have 
been isolated from plants based on their traditional use. 
These are also considered to be useful in eradicating the 
adverse effects of various chemotherapeutic agents as 
well as in prolonging longevity and attaining positive 
general health [15]. They produce different secondary 
metabolites generally called phytochemicals (flavonoids, 
alkaloids, terpenoids, polyphenolics etc.) which have 
anticancer potential and can be used as an alternative 
cancer drug resources [16,17]. Therefore, this study was 
designed to find out anticancer potential of 
phytochemicals which could target CDK2 and inhibit its 
over-expression by using in-silico methods (molecular 
docking and drug scan). The result of this study will 
facilitate the researchers to improve the status of 
anticancer therapeutics by diversifying the scaffolds of 
CDKs inhibitors.   
Methods 
Structure based virtual screening strategy was applied 
through  high performing computing work station with  
following specifications (Intel(R) Core(TM) i5-3210M 
CPU @ 2.50 GHz, 5 Core(s) processor with 4.00 GB 
RAM and 64-bit Windows-8 Operating System).  
Structure based drug screening was performed with 
Molecular Operating Environment (MOE v2009) [18].  
Ligand database preparation and receptor protein 
refinement 
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Structures of phytochemicals were retrieved from 
MPD3 database [19], MAPS database [20], ZINC 
database [21] and PubChem [22]. Ligand library 
composed of 2300 compounds was optimized for 
docking. Optimization involves addition of partial 
charges and energy minimization of selected compound 
through Protonate-3D and MMFF94X force field 
respectively. Optimized ligands files were stored in 
ligand database which was used later as an input file for 
docking studies. 
CDK2 structure refinement 
Likewise, three-dimensional structure of CDK2 was 
retrieved from the Protein Data Bank (PDB) using PDB 
ID: 3PXF with 1.8Å resolution [23]. To refine the 
protein structure, already bound ligands and water 
molecules were removed from the structure, 3D 
protonation and energy minimization was done in 
MOE. The minimized structure was used for docking in 
subsequent steps. 
Molecular docking 
MOE docking tool was used to dock phytochemical 
ligand library against allosteric ligand binding site of 
CDK2. Potential binding pocket containing the reported 
residue (Lys56) was identified with the help of site finder 
tool of MOE and was further taken through docking 
process. Ten best docked poses were generated through 
applying a scoring function London dG. Refinement of 
docking procedure was done by applying forcefield 
algorithm which keeps the receptor rigid. From them, 
best interacting ligands, molecules were screened on the 
basis of RMSD (Root-Mean-Square Deviation) which is 
usually measured in Angstrom (Å), and docking score. 
Already reported co-crystallized ligand, Fluorophore-8-
anilino-1 naphthalene sulfonate (ANS) was used as a 
reference compound for docking into native CDK2 
pocket to validate our docking result. Ligand receptor 
interaction analysis was done through LigX tool in 
MOE. It is designed to show potential residues 
interacting with the ligand molecules graphically. It 
generates 2D images representing the forces stabilizing 
ligand molecules within binding pockets of receptors. 
Drug scan 
To analyze the drug likeliness of screened 
phytochemical based lead molecules drug scan of final 
selected phytochemical hits was performed in MOE by 
ligand properties checking tool. Compounds were 
further filtered on the basis of the bearing appropriate 
molecular properties to be a drug candidate. 
Results 
Analysis of allosteric binding of 2300 phytochemical 
based small molecules to CDK2 receptor initially 
revealed 10 compounds which fit well within the 
binding pockets with low S-score. Iterative docking of 
the best docked 10 molecules within receptor pocket, 
originally occupied by co crystallized inhibitor 
Fluorophore-8-anilino-1 naphthalene sulfonate (ANS), 
resulted in 4 best phytochemicals with dock score 
comparatively less than the original one.  
Chemical structure of our four selected 
phytochemicals; Khusenol T, Remangiflavanone B, 
Neocalyxins A and Elenoside are shown in Figure 1. 
Khusenol T (Fig1A) is an essentail oil compund 
(C15H24O) isolated from Angola vetiver [20], 
Remangiflavanone B (Fig1B) is a tetrahydroxyflavanone 
aromatic compound (C25H28O6) isolated from Physena 
madagascariensis [24], Neocalyxins A (Fig1C) is a 
diarylheptanoids extracted from Alpinia blepharocalyx 
seeds [25] and Elenoside (Fig1D), commonly known as 
arylnapthalene lignan is extracted from Justicia 
hyssopifolia [26]. 
 
Figure 1: 2D chemical structures of Khusenol T, Remangiflavanone B, 
Neocalyxins A and Elenoside. 
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Binding affinity analysis of selected compounds through 
LigX shown in Figure 2, revealed that top ranked 
molecules experience water mediated binding with the 
crucial catalytic residues of pocket.  
 
Figure 2: LigX interaction diagram representing binding pattern of 
Khusenol T, Remangiflavanone B, Neocalyxins A and Elenoside with 
binding pocket residues of CDK2 receptor protein. 
Spatial position of Kushenol T is stabalized  within the 
pocket (Figure 2A) with the  lowest S-score (-17.83) and 
interacting through hydrogen bonds with Tyr15 and 
Phe146 while rest of close lying residues (Lys33, Ileu52, 
Lys56, Leu78, Phe80, Asp145) are having weak 
electrstatic interactions with Kushenol T. Following this 
is Remangiflavanone B inlaid within the same binding 
pocket as shown in Figure 2B, lying closer to Tyr15, 
Lys33, Ileu52, Leu55, Lys56, Leu66, Leu76, Leu78, 
phe80, Asp145 and Phe146 residues  of CDK2 binding 
pocket with dock score -17.57 kcal/mol. Third best 
screened compound Neocalyxins A experiences water 
mediated and hydrogen bonding with Tyr15, Lys33, 
Asp145 and Phe146 while other closely lying  residues 
are Ileu52, Leu55, Lys56, Val64,  Leu66, Leu78 and 
Phe8o shown in Figure 2C. Elenoside has been shown to 
in laid well within the binding pocket showing water 
mediated interaction with Leu55, Lys56, in addition to 
non-covalent interactions with Val64 (Figure 2D). 
While calcualted RMSD value of all the four selected 
inhibitors with respecct to their co-crytallized CDK2 
Fluorophore-8-anilino-1 naphthalene sulfonate (ANS) 
complex is given in Table 1, while binding conformation 
of each ligand inside the binding pocket of CDK2 is 
represented in Figure 3. 
Drug scan 
To verify the drug ability of selected phytochemicals, 
ligand properties were calculated with LigX tool of 
MOE. All selected phytochemicals showed positive 
results and fulfill the criteria of the Lipinski’s rule of five 
[27]. The rule describes that potential drug like 
compound should not have more than 5 hydrogen 
bond donors, maximum 10 hydrogen bond acceptors, 
molecular mass less than 500 daltons, and an octanol-
water partition coefficient log P not greater than 5.  
Drug scan results are given in Table 1. 
 
Figure 1: Illustration of 3D spatial orientation of Khusenol T, 
Remangiflavanone B, Neocalyxins A and Elenoside within the 
allaostreic binding pocket of CDK2 receptor protein. 
Discussion  
In eukaryotes, cell’s count is critically regulated by the 
release of growth promoting factors that dictate the 
entry of cell into subsequent cycles of Cell cycle. 
Cancerous cells lose their homeostatic control over 
growth promoting signal which render them as master 
of their own fate [28]. Cyclin-dependent kinases (CDKs) 
are serine/threonine protein kinases that are intimately 
engaged in regulating cell division cycle.  Six CDKs have 
been identified so far in mammal, each one is required 
to make complex with cyclins at different stages of cell 
cycle. Cyclin-CDKs complex functions as a cell cycle 
checkpoint which arrest the cell cycle progression in 
case of DNA damage.  Activity of CDKs is governed by 
its complex formation with Cyclin through 100 amino 
acid long cyclin box. Cyclin-Dependent kinase-2 
(CDK2) complexed to Cyclin E and cyclin A at G/S 
junction and S phase  of cell cycle clock  respectively are 
important for continued replication of DNA, DNA 
damage repair phosphorylation and transcription of  
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necessary growth factors [29]. Normal cells acquire the 
hallmarks of cancer and attain limitless cell replication 
potential. To inhibit the process of carcinogenesis, 
CDKs-cyclin complexes are attractive anti therapeutics 
targets. To cope with the constant need of novel and 
effective small molecule, anti-cancer therapeutics with 
minimal side effects, research is now focusing more on 
computational drug discovery [16]. Multiple studies 
reported anticancer potential of phytochemicals 
through computer aided drug design [30-32]. 
Despite of efforts spanning over 20 years only one 
FDA approved CDK2 inhibitor is available in market 
while rest of discovered CDK2 inhibitors are in clinical 
trial. To fasten the drug approval procedure and to 
discover more efficacious inhibitors with novel scaffolds 
that can improve the anticancer therapeutics status, 
computational drug discovery approaches are highly 
reliable. Current study aimed at phytochemical 
screening for potential CDK2 inhibitor.  Idea of using 
phytochemicals instead of synthetic compounds for 
drug screening is to minimize the multifaceted side 
effects posed by multitargeting of other signalling 
proteins in addition to CDK2. Medicinal plants have 
been used for centuries to cure different diseases [33-
35]. Medicinal plants produce different secondary 
metabolites generally called phytochemicals (flavonoids, 
alkaloids, terpenoids, polyphenolics etc) which have 
anticancer potential and can be used as an alternative 
drug resource [15,32].  
Form the ground-breaking detail of structural 
diversity among natural products, virtual screening was 
done to discover novel allosteric compound for 
regulation of dysfunctional CDK2. Allosteric regulation 
has been reported as effective strategy to attain  
 
 
 
 
 
 
 
 
 
 
 
 
irreversible inhibition. Studies reports that high 
similarity within the ATP binding site of CDK2 with 
other cell cycle signalling protein results in off target 
binding of inhibitors [29,36]. To deal with the daunting 
task of selectivity and specificity of CDK2 inhibitors, 
current study is devoted to allosteric regulation for 
desired results.  
Spatial orientation and dock score of current reported 
four top-ranked leads reveals efficient binding of 
functional residues with maximum binding affinity.  
Moreover, these compounds meet the drug likelihood 
criteria shown in Table1 and may prove excellent ready 
to use starting point. A study by Lima and co-workers 
established the role Khusenol T as anti-inflammatory 
and antinociceptive which is thought to relief pain in 
pathological disease [37].  Antimicrobial potential of 
Remangiflavanone B has also been reported in past 
study [24], while Neocalyxins A is known for its 
cytotoxic role in tumor cells [25]. In addition to this 
Elenoside has been reported as a cytotoxic bioactive 
molecule in in vitro. Along with this central nervous 
activity and its role as cardiac muscles vasodilator has 
also been reported [26]. Looking at the anticancer drug 
potential of aforementioned phytochemicals, current 
study was an endeavour to exploit the chemical nature 
of four selected phytochemicals for inhibitions of 
limitless proliferation of tumour cells by inhibiting 
CDK2 protein.  
Current molecular docking study has shown the 
important interactions of medicinal plant 
phytochemicals with CDK2 binding site. Kushenol T, 
Remangiflavanone B, Neocalyxins A and Elenoside 
showed the low S score as compared to the ANS and also 
interacts strongly with all eight residues of CDK2 
MPD3 ID Phytochemical S score RMSD Residues in contact Lipinski’s rule of five 
690 Kushenol T -17.83 2.27 Å Tyr15, Lys33, Ileu52, Leu55, 
Lys56, Leu66, Leu76, Leu78, 
phe80, Asp145, Phe146 
MW:426.59, Log 
p:4.8,TPSA:107.22, H don:4, H 
acc:6 
686 Remangiflavanone 
B 
-17.57 1.08 Å Tyr15, Lys33, Ileu52, Leu55, 
Lys56, Leu66, Leu76, Leu78, 
phe80, Asp145, Phe146 
MW:424.49, Log p:5.4, 
TPSA:107.22, H don:4, H acc:6 
1904 Neocalyxins A -17.26 1.07 Å Tyr15, Lys33, Ileu52, Leu55, 
Lys56, Val64,  Leu66, Leu78, 
phe80, Asp145, Phe146 
MW:474.50, Log p:5.1, 
TPSA:94.45, H don:2, H acc:7 
1620 Elenoside -17.17 1.28 Å Tyr15, Lys33, Ileu52, Leu55, 
Lys56, Val64, Leu65, Leu75, 
Leu78, phe80, Asp145, Phe146 
MW:498.44, Log p:1.0, 
TPSA:164.37, H don:5, H acc:10 
Reference  ANS -10.83 1.88 Å Tyr15, Lys33, Ileu52, Lys56, 
Leu78, phe80, Asp145, Phe146 
MW:299.35, Log p:2.03, 
TPSA:66.40, H don:2, H acc:4 
Table 1: Detail and properties of selected phytochemicals 
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binding site. These phytochemicals successfully block 
the CDK2. Thus, it can be concluded from this study 
that these phytochemicals can be used as strong anti-
cancer agents against CDK2 in future. 
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